17α-hydroxylase/17,20-lyase (P45017α) inhibitors in the treatment of prostate cancer: A review

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 613-626

  Owen, Caroline P ^a  

^a KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Enzyme; Hydroxylase; Inhibitors; Lyase; Prostate cancer

Indexed keywords

20EPSILON HYDROXY 21 TRIFLUROPREGNANE; ABIRATERONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; FINASTERIDE; IMIDAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; KETOCONAZOLE; OXIME DERIVATIVE; PREGNENOLONE DERIVATIVE; PROGESTERONE DERIVATIVE; PYRAZOLE DERIVATIVE; STEROID 17,20 LYASE; STEROID 17,20 LYASE INHIBITOR; STEROID 17ALPHA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE INHIBITOR; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVE SITE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HUMAN; LIVER TOXICITY; NONHUMAN; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TREATMENT DURATION; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; ENZYMOLOGY; MALE; METABOLISM; PROSTATE TUMOR; STEREOISOMERISM;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR CONFORMATION; PROSTATIC NEOPLASMS; STEREOISOMERISM; STEROID 17-ALPHA-HYDROXYLASE;

EID: 70349120414     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788680046     Document Type: Review

References (81)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58, 71-96.
2. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Columbey, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581-592.
3. Bruchovsky, N. And Wilson, J. D. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 1968, 243, 2012-2021.
4. Labrie, F.; Bélanger, A.; Cusan, L.; Séguin, C.; Pelletier, G.; Kelly, P. A.; Lemay, A.; Raynaud, J. P. Antifertility effects of LHRH agonists in the male. J. Androl., 1980, 1, 209-228.
5. Faure, N.; Labrie, F.; Lemay, A.; Bélanger, A.; Gourdeau, Y.; Laroche, B.; Robert, G. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertil. Steril., 1982, 37, 416-424.
6. Oefelein, M. G. and Cornum, R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J. Urol., 2000, 164, 726-729.
7. Morote, J.; Esquena, S.; Abascal, J. M.; Trilla, E.; Cecchini, L.; Raventos, C. X.; Catalan, R.; Reventos, J. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol. Int., 2006, 77, 135-138.
8. Yri, O. E.; Bjoro, T.; Fossa, S. D. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur. Urol., 2006, 49, 54-58.
9. Adams, J. B. Control of secretion and the function of C19-delta 5-steroids of the human adrenal gland. Mol. Cell. Endocrinol., 1985, 41, 1-17.
10. Nakamura, Y.; Suzuki, T.; Nakabayashi, M.; Endoh, M.; Sakamoto, K, Mikami, Y.; Moriya, T.; Ito, A.; Takahashi, S.; Yamada, S.; Arai, Y.; Sasano, H. In situ androgen producing enzymes in human prostate cancer. Endocr. Relat. Cancer, 2005, 12, 101-107.
11. Labrie, F.; Bélanger, A.; Luu-The, V.; Labrie, C.; Simard, J.; Cusan, L.; Gomez, J.; Candas, B. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr. Rev., 2005, 26, 361-379.
12. Picado-Leonard, J. and Miller, W. L. Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA, 1987, 6, 439-448.
13. 5-steroid-17,20-lyase reactions. Endocr. Rev., 1989, 3, 968-975.
14. Brock, B. J. and Waterman, M. R. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. Biochemistry, 1999, 38, 1598-1606.
15. Chung, B.; Picado-Leonard, J.; Haniu, M.; Bienkowski, M.; Hall, P. F.; Shively, J. E.; Miller, W. L. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc. Natl. Acad. Sci. USA, 1987, 84, 407-411.
16. McCague, R.; Rowlands, M. G.; Barrie, S. E.; Houghton, J. Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid. J. Med. Chem., 1990, 33, 3050-3055.
17. Njar, V. C. O. and Brodie, A. M. H. Inhibitors of 17 alpha-hydroxylase -C17,20-lyase (P-450 17 alpha): potential agents for the treatment of prostate cancer. Curr. Pharm. Des., 1999, 5, 163-180.
18. Katagiri, M.; Kagawa, N.; Waterman, M. R. The role of cytochrome b5 in the biosynthesis of androgens by human P450c17. Arch. Biochem. Biophys., 1995, 317, 343-347.
19. Lee-Robichaud, P.; Shyadehi, A. Z.; Wright, J. N.; Akhtar, M. E.; Akhtar, M. Mechanistic kinship between hydroxylation and desaturation reactions: acyl-carbon bond cleavage promoted by pig and human CYP17 (P-450(17)alpha; 17 alpha-hydroxylase-17,20-lyase). Biochemistry, 1995, 34, 14104-14113.
20. Akhtar, M. K.; Kelly, S. L.; Kaderbhai, M. A. Cytochrome b(5) modulation of 17{alpha} hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J. Endocrinol., 2005, 187, 267-274.
21. Groves, J. T.; McClusky, G. A.; White, R. E.; Coon, M. Aliphatic hydroxylation by highly purified liver microsomal cytochrome P-450. Evidence for a free radical intermediate. J. Biochem. Biophys. Res. Commun., 1978, 81, 154-160.
22. Ortiz de Montellano, P. R. Cytochrome P-450: Structure, Mechanism and Biochemistry. Ortiz de Montellano, P. R. Ed.; Plenum Press: New York 1986, pp. 217-271.
23. Ortiz de Montellano, P. R. And Stearns, R. A. Timing of the radical recombination step in cytochrome P-450 catalysis with ring-strained probes. J. Am. Chem. Soc., 1987, 109, 3415-3420.
24. Atkinson, J. K. And Ingold, K. U. Cytochrome P450 hydroxylation of hydrocarbons: variation in the rate of oxygen rebound using cyclopropyl radical clocks including two new ultrafast probes. Biochemistry, 1993, 32, 9209-9214.
25. Akhtar, M.; Njar, V. C. O.; Wright, J. N. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J. Steroid Biochem. Mol. Biol., 1993, 44, 375-387.
26. 17α. Biochemistry, 1994, 33, 4410-4418.
27. Ahmed, S and Owen, C. P. Mechanism of 17 alpha-hydroxylase/17,20-lyase - an initial geometric perspective for the lyase of the C(17)-C(20) bond of C21 steroids. Bioorg. Med. Chem. Lett., 1998, 8, 1023-1028.
28. Auchus, R. J. and Miller, W. L. Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol. Endocr., 1999, 13, 1169-1182.
29. Laughton, C. A.; Zvelebil, M. J. J. M.; Neidle, S. Sternberg, M. J. E. A molecular model for the enzyme cytochrome P450(17 alpha), a major target for the chemotherapy of prostatic cancer. Biochem. Biophys. Res. Commun., 1990, 171, 1160-1167.
30. Burke, D. F.; Laughton, C. A.; Neidle, S. Homology modelling of the enzyme P450 17α-hydroxylase/17,20-lyase - a target for prostate cancer chemotherapy - from the crystal structure of P450BM-3. Anti-Cancer Drug Des., 1997, 12, 113-123.
31. Lewis, D. F. V. and Lee-Robichaud,. P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J. Steroid Biochem. Mol. Biol., 1998, 66, 217, 233.
32. Schappach, A. and Höltje, H.-D. Molecular modelling of 17 alpha-hydroxylase-17,20-lyase. Pharmazie, 2001, 56, 435-442.
33. Schappach, A. and Höltje, H.-D. Investigations on inhibitors of human 17 alpha-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17 alpha-hydroxylase-17,20-lyase, Part II. Pharmazie, 2001, 56, 835-842.
34. Clement, O. O.; Freeman, C. M.; Hartmann, R. W.; Handratta, V. D.; Vasaitis, T. S.; Brodie, A. M. H.; Njar, V. C. O. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J. Med. Chem., 2003, 46, 2345-2351.
35. Matsunaga, N.; Kaku, T.; Itoh, F.; Tanaka, T.; Hara, T.; Miki, H.; Iwasaki, M.; Aono, T.; Yamaoka, M.; Kusaka, M.; Tasaka, A. C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors. Bioorg. Med. Chem., 2004, 12, 2251-2273.
36. Matsunaga, N.; Kaku, T.; Ojida, T.; Tanaka, T.; Hara, T.; Yamaoka, M.; Kusaka, M.; Tasaka, A. C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors. Bioorg. Med. Chem., 2004, 12, 4313-4336.
37. Ahmed, S. The use of the novel substrate-heme complex approach in the derivation of a representation of the active site of the enzyme complex 17alpha-hydroxylase and 17,20-lyase. Biochem. Biophys. Res. Commun., 2004, 316, 595-598.
38. Angelastro, M. R.; Laughlin, M. E.; Schatzman, G. L.; Bey, P.; Blohm, T. R. 17 beta-(cyclopropylamino)-androst-5-en-3 beta-ol, a selective mechanism-based inhibitor of cytochrome P450(17 alpha) (steroid 17 alpha-hydroxylase/C17-20 lyase). Biochem. Biophys. Res. Commun., 1989, 162, 1571-1577.
39. Angelastro, M. R.; Marquart, A. L.; Weintraub, P. M.; Gates, C. A.; Laughlin, M. E.; Blohm, T. R.; Peet, N. P. Time-dependent in-activation of steroid C17(20) lyase by 17β-cyclopropyl ether-substituted steroids. Bioorg. Med. Chem. Lett., 1996, 6, 97-100.
40. Burkhart, J. P.; Weintraub, P. M.; Gates, C. A.; Resvick, R. J.; Vaz, R. J.; Friedrich, D.; Angelastro, M. R.; Bey, P.; Peet, N. P. Novel steroidal vinyl fluorides as inhibitors of steroid C17(20) lyase. Bioorg. Med. Chem., 2002, 10, 929-934.
41. Weintraub, P. M.; Holland, A. K.; Gates, C. A.; Moore, W. R.; Resvick, R. J.; Bey, P. Peet, N. P. Synthesis of 21,21-difluoro-3 beta-hydroxy-20-methylpregna-5,20-diene and 5,16,20-triene as potential inhibitors of steroid C17(20) lyase. Bioorg. Med. Chem., 2003, 11, 427-431.
42. Schenkman, J. B.; Remmer, H.; Estabrook, R. W. Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol., 1967, 3, 113-123.
43. Dawson, J. H.; Anderson, L. A.; Sono, M. Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme. J. Biol. Chem., 1982, 257, 3606-3617.
44. Hall, P. F. Cytochromes P-450 and the regulation of steroid synthesis. Cytochromes P-450 and the regulation of steroid synthesis. Steroids, 1986, 48, 133-96.
45. Li, J.; Li, Y.; Son, C.; Brodie, A. M. H. Synthesis and evaluation of pregnane derivatives as inhibitors of human testicular 17 alpha-hydroxylase/C17,20-lyase. J. Med. Chem., 1996, 39, 4335-4339.
46. Hartmann, R. W.; Hector, M.; Haidar, S.; Ehmer, P. B.; Reichert, W.; Jose, J. Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2. J. Med. Chem., 2000, 43, 4266-4277.
47. Ling, Y.; Li, J.; Kato, K.; Liu, Y.; Wang, X.; Klus, G. T.; Marat, K.; Nnane, I. P.; Brodie, A. M. H. Synthesis and in vitro activity of some epimeric 20 alpha-hydroxy, 20-oxime and aziridine pregnene derivatives as inhibitors of human 17 alpha-hydroxylase/C17,20-lyase and 5 alpha-reductase. Bioorg. Med. Chem., 1998, 6, 1683-1693.
48. Njar, V. C. O.; Klus, G. T.; Johnson, H. H.; Brodie, A. M. H. Synthesis of novel 21-trifluoropregnane steroids: inhibitors of 17 alpha-hydroxylase/17,20-lyase (17 alpha-lyase). Steroids, 1997, 62, 468-473.
49. Auchus, R. J.; Kumar, A. S.; Boswell, C. A.; Gupta, M. K.; Bruce, K.; Rath, N. P.; Covey, D. F. The enantiomer of progesterone (entprogesterone) is a competitive inhibitor of human cytochromes P450c17 and P450c21. Arch. Biochem. Biophys., 2003, 409, 134-144.
50. Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem., 1995, 38, 2463-2471.
51. Rowlands, M. G.; Barrie, S. E.; Chan, F.; Houghton, J.; Jarman, M.; McCague, R.; Potter, G. A. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J. Med. Chem., 1995, 38, 4191-4197.
52. O'Donnell, A.; Judson, I.; Dowsett, M.; Raynaud, F.; Dearnaley, D.; Mason, M.; Harland, S.; Robbins, A.; Halbert, G.; Nutley, B.; Jarman, M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer, 2004, 90, 2317-2325.
53. Jarman, M.; Barrie, S. E.; Llera, J. M. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J. Med. Chem., 1998, 41, 5375-5381.
54. Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol., 2003, 84, 555-562.
55. Ling, Y.; Li, J.; Liu, Y.; Kato, K.; Klus, G. T.; Brodie, A. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha). J. Med. Chem., 1997, 40, 3297-3304.
56. Nnane, I. P.; Long, B. J.; Ling, Y, Grigoryev, D. N.; Brodie, A. M. Anti-tumour effects and pharmacokinetic profile of 17-(5′-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Br. J. Cancer, 2000, 83, 74-82.
57. Long, B. J.; Grigoryev, D. N.; Nnane, I. P.; Liu, Y.; Ling, Y.; Brodie, A. M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res., 2000, 60, 6630-6640.
58. Njar, V. C. O.; Kato, K.; Nnane, I. P.; Grigoryev, D. N.; Long, B. J.; Brodie, A. M. H. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J. Med. Chem., 1998, 41, 902-912.
59. Nnane, I. P.; Njar, V. C. O.;Liu, Y.; Lu, Q.; Brodie, A. M. H. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo. J. Steroid Biochem. Mol. Biol., 1999, 71, 145-152.
60. Handratta, V. D.; Jelovac, D.; Long, B. J.; Kataria, R.; Nnane, I. P.; Njar, V. C. O.; Brodie, A. M. H. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. J. Steroid Biochem. Mol. Biol., 2004, 92, 155-165.
61. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D.; Farquhar, R.; Guo, Z. Y.; Qiu, Y.; Brodie, A. M. H. Novel C-17-heteroaryl steroidal CYP17 inhibitors/ antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem., 2005, 48, 2972-2984.
62. Barrie, S. E.; Potter, G. A.; Goddard, P. M.; Haynes, B. P.; Dowsett, M; Jarman, M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol., 1994, 50, 267-273.
63. DeFelice, R.; Johnson, D. G.; Galgiani, J. N. Gynecomastia with ketoconazole. Antimicrob. Agents Chemother., 1981, 19, 1073-1074.
64. Pont, A.; Williams, P. L.; Azhar, S.; Reitz, R. E. Ketoconazole blocks testosterone synthesis. Arch. Intern. Med., 1982, 142, 2137-2140.
65. Loose, D. S.; Kan, P. B.; Hirst, M. A.; Marcus, R. A.; Feldman, D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J. Clin. Invest., 1983, 71, 1495-1499.
66. Trachtenberg, J. Ketoconazole therapy in advanced prostatic cancer. J. Urol., 1984, 132, 61-63.
67. Pont, A.; Williams, P.L.; Loose, D. S.; Feldman, D.; Reitz, R.E.; Bochra, C.; Stevens, D. A. Ketoconazole blocks adrenal steroid synthesis. Ann. Intern. Med., 1982, 97, 370-372.
68. Nagai, K.; Miyamori, I.; Ikeda, M.; Koshida, H.; Takeda, R.; Suhara, K.; Katagiri, M. Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalyzed reactions. J. Steroid Biochem., 1986, 24, 321-323.
69. Figg, W. D.; Liu, Y.; Arlen, P.; Gulley, J.; Steinberg, S. M.; Liewehr, D. J.; Cox, M. C.; Zhai, S. P.; Cremers, S.; Parr, A.; Yang, X. W.; Chen, C. C.; Jones, E.; Dahut, W. L. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J. Urol., 2005, 173, 790-796.
70. Nakabayashi, M.; Xie, W.; Regan, M. M.; Jackman, D. M.; Kantoff, P. W.; Oh, W. K. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer, 2006, 107, 975-981.
71. Eklund, J.; Kozloff, M.; Vlamakis, J.; Starr, A.; Marriott, M.; Gallot, L.; Jovanovic, B.; Schilder, L.; Robin, E.; Pins, M.; Bergan, R. C. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Cancer, 2006, 106, 2459-2465.
72. Ideyama, Y.; Kudoh, M.; Tanimoto, K.; Susaki, Y.; Nanya, T.; Nakahara, T.; Ishikawa, H.; Yoden, T.; Okada, M.; Fujikura, T.; Azaka, H.; Shikama, H. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate, 1998, 37, 10-18.
73. Ideyama, Y.; Kudoh, M.; Tanimoto, K.; Susaki, Y.; Nanya, T.; Nakahara, T.; Ishikawa, H.; Fujikura, T.; Azaka, H.; Shikama, H. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn. J. Pharmacol., 1999, 79, 213-220.
74. Wachall, B. G.; Hector, M.; Zhuang, Y.; Hartmann, R. W. Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17alphahydroxylase-C17, 20-lyase (P450 17). Bioorg. Med. Chem., 1999, 7, 1913-1924.
75. Zhuang, Y.; Wachall, B. G.; Hartmann, R. W. Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17alpha-hydroxylase-C17, 20-lyase (P450 17). Bioorg. Med. Chem., 2000, 8, 1245-1252.
76. Leroux, F.; Hutschenreuter, T. U.; Charrière, C.; Scopelliti, R.; Hartmann, R. W. N-(4-Biphenylmethyl)imidazoles as potential therapeutics for the treatment of prostate cancer: metabolic robustness due to fluorine substitution? Helv. Chim. Acta., 2003, 86, 2671-2686.
77. Hartmann, R. W.; Palusczak, A.; Lacan, F.; Ricci, G.; Ruzziconi, R. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)). J. Enzym Inhib. Med. Chem., 2004, 19, 145-155.
78. Ahmed, S. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/ 17,20-lyase (P450(17alpha)). Bioorg. Med. Chem. Lett., 1995, 5, 2795-2800.
79. Owen, C. P.; Dhanani, S.; Patel, C. H.; Shahid, I., Ahmed, S. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450(17alpha)). Bioorg. Med. Chem. Lett., 2006, 16, 4011-4015.
80. Patel, C. H.; Dhanani, S.; Owen, C. P.; Ahmed, S. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17alpha-hydroxylase/17,20-lyase (P450 (17alpha)). Bioorg. Med. Chem. Lett., 2006, 16, 4752-4756.
81. 17α). J. Steroid Biochem. Mol. Biol., 2008, 110, 18-29.